Login / Signup

Risk of hepatitis B reactivation is controllable in patients with B-cell lymphoma receiving anti-CD19 CAR T cell therapy.

Wei LiuWenyang HuangMin WangRui LvJian LiYing WangShuhui DengShuhua YiHong LiuQing RaoYingxi XuLulu LvLugui QiuDehui ZouJian-Xiang Wang
Published in: British journal of haematology (2020)
Keyphrases
  • cell therapy
  • stem cells
  • diffuse large b cell lymphoma
  • mesenchymal stem cells
  • nk cells